News - Company News

Global opportunity emerges as Remplir™ is used in nerve-sparing prostate cancer surgery

Remplir™ Real World Evidence study delivers compelling 81% success rate

First US Sales Revenue from Remplir™

Orthocell has today reached a critical milestone in the commercialisation of Remplir™ in the US$1.6 Billion US market, recording its first sales revenue from the nerve repair product in the US.

First US Surgical Use of Remplir™ 

Orthocell recorded first use of Remplir™ in the US overnight, which is an important step in establishing surgical experience and knowledge of the product. 

Orthocell Appoints its First Four US Remplir™ Distributors

Orthocell has appointed four US distributors for its flagship nerve repair product Remplir™, enabling the commencement of commercial distribution into the US.

Orthocell Appoints Exclusive Distributor to Commence Sales of Remplir™ in Singapore

Orthocell has announced that it has appointed Device Technologies Asia as the exclusive distributor of market leading peripheral nerve repair device Remplir™ in Singapore.

Meet The Board | Independent Director, Dr. Ravi Thadhani

In this episode of Orthocell’s ‘Meet the Board’ video series, we feature Independent Director, Dr. Ravi Thadhani.

Appointment of Key US Executives to Lead Remplir™ Launch

Orthocell has appointed two experienced US-based executives to drive the market launch and sales of Remplir™ following the expected US FDA approval in the first quarter of 2025.